• News
  • Publications
  • Videos
  • Events
  • About
  • Contact

Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.

September 9, 2019

Abstract PURPOSE: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are primary KRAS effector pathways, but combined MAPK and PI3K inhibition has not been demonstrated to be clinically effective to date. We explore the resistance mechanisms uniquely employed by malignant cells. EXPERIMENTAL DESIGN: We […]

View Original Source at Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.

Weekly Digest

Sign up to receive
weekly updates!

    No Spum Guarantee

    Cancer Types

    • Bladder Cancer Research (2)
    • Bowel Cancer Research (3)
    • Brain Cancer Research (7)
    • Breast cancer (6)
    • cervical cancer (1)
    • colon (1)
    • Colon cancer (14)
    • colorectal cancer (6)
    • Drug development (12)
    • Endometrial cancer (2)
    • Esophageal cancer (3)
    • Gastric cancer (5)
    • Hans Clevers (1)
    • Head and neck cancer (4)
    • Immunotherapy (0)
    • Intestinal cancer (8)
    • intestinal organoids (1)
    • Kidney cancer (3)
    • Leukemia (1)
    • Liver cancer (11)
    • Lung cancer (4)
    • melanoma (1)
    • metastatic cancer (1)
    • Organoid (143)
    • Ovarian cancer (8)
    • Pancreatic cancer (19)
    • Peritoneal cancer (1)
    • Personalized medicine (5)
    • Prostate cancer (7)
    • Rectal cancer (1)
    • solid tumor (1)
    • stem cells (1)

    ORG
    1-617-547-9443

    Monday-Friday: 8 am - 8 pm
    Saturday: 8 am - 4:30 pm

    • News
    • Publications
    • Videos
    • Events
    • About Us
    • Contact Us
    • Privacy
    • Terms of Use

    © COPYRIGHT 2023 Organoid Research Group. ALL RIGHTS RESERVED.